IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky

The following are some of the biotech stocks that made their way onto the Day’s Gainers & Losers’ list of August 31, 2017.

GAINERS

1. Impax Laboratories Inc. (IPXL)

Gained 20.61% to close Thursday’s (Aug. 31) trading at $21.65.

News: A SEC filing shows that China-based Shanghai Fosun Pharmaceutical (Group) Co. Ltd. owns 5.19% stake in the Company.

2. NewLink Genetics Corp. (NLNK)

Gained 14.37% to close Thursday trading at $8.12.

News: No news

Upcoming events:

The company will be participating in:

— Baird Global Healthcare Conference on September 7 at 1:25pm ET in New York City.
— Cantor Fitzgerald Global Healthcare Conference on September 25 at 4:10pm ET in New York City.

Near-term catalysts:

— Updated data from phase II trial of Indoximod plus Gemcitabine/Nab-paclitaxel for patients with metastatic pancreatic cancer to be presented at an oncology meeting in late 2017 or early 2018.
— Initiation of a pivotal trial of Indoximod in combination with PD-1 checkpoint blockade for patients with advanced melanoma, with the goal of full enrollment by end of 2018.

3. Presbia PLC (LENS)

Gained 11.99% to close Thursday trading at $2.99.

News: No news

Pipeline:

The Company’s lead product candidate is Presbia Flexivue Microlens, a revolutionary optical lens implant for treating presbyopia, the age-related loss of near vision.

Near-term catalyst:

The Company expects to seek approval of Presbia Flexivue Microlens in the fourth quarter of this year.

4. Adaptimmune Therapeutics plc (ADAP)

Gained 12.36% to close Thursday trading at $7.00.

The Company is focused on developing enhanced T-cell therapies that work with the immune system to improve detection and targeting of cancer cells, resulting in destruction of those cancer cells.

News: No news

Pipeline:

The advanced drug candidate in the pipeline is NY-ESO TCR therapeutic candidate, under multiple Phase 1/2 clinical trials in patients with solid tumors and hematological malignancies including synovial sarcoma, multiple myeloma, melanoma, NSCLC and ovarian cancer. NY-ESO TCR therapeutic candidate in being developed in partnership with GSK.

The Company’s wholly-owned product candidates are MAGE-A10 T-cell therapy, under phase I/II studies in lung cancer, bladder, melanoma and head and neck cancers; AFP TCR, under phase I study in patients with hepatocellular carcinoma, and MAGE-A4 TCR, under phase I trial in multiple solid tumors.

5. Cara Therapeutics Inc. (CARA)

Gained 11.43% to close Thursday trading at $14.33.

News: The Company will be…

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *